Rainier Acquisition raises total IPO proceeds to $86.25M after over-allotment
- Rainier Acquisition Corp raised total IPO gross proceeds to $86.25M after full over-allotment exercise
- Additional 1.125 million units sold at $10.00 each, adding to initial 7.5 million units
- Total trust account balance stands at $86.25M following September 2, 2026 closing
- Chardan served as sole book-running manager for the Nasdaq-listed SPAC offering
*this image is generated using AI for illustrative purposes only.
Rainier Acquisition Corporation announced on September 2, 2026, that the underwriter fully exercised its over-allotment option, bringing total initial public offering gross proceeds to $86,250,000. This update supersedes the earlier closing of $75,000,000 from August 28, 2026.
The underwriter purchased an additional 1,125,000 units at $10.00 per unit. Combined with the initial 7,500,000 units, the total units sold in the IPO now stand at 8,625,000. Following this closing, an aggregate of $86,250,000 is held in the Company’s trust account.
Updated Offering Details
Each unit consists of one Class A ordinary share and one-quarter of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share at $11.50. No fractional warrants are issued upon separation; only whole warrants trade.
| Component | Detail |
|---|---|
| Total Units Sold | 8,625,000 |
| Price Per Unit | $10.00 |
| Total Gross Proceeds | $86,250,000 |
| Trust Account Balance | $86,250,000 |
| Warrant Exercise Price | $11.50 |
| Ticker Symbols | RNAQU (Units), RNAQ (Shares), RNAQW (Warrants) |
The units began trading on The Nasdaq Capital Market under the ticker symbol RNAQU on August 27, 2026. Once separate trading begins, Class A ordinary shares and warrants will be listed under RNAQ and RNAQW, respectively.
Chardan acted as the sole book-running manager for the offering. The offering was made only by means of a prospectus, copies of which may be obtained from Chardan at 1 Pennsylvania Plaza, Suite 4800, New York, New York 10119, or by email at prospectus@chardan.com .
Strategic Focus and Management
The Company intends to focus its search on global life sciences industries, including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing, and related subsectors. Its efforts to identify a prospective target business will not be limited to any particular industry or geographical region.
The management team is led by Gbola Amusa, MD, CFA, Chief Executive Officer, and Guy Barudin, Chief Financial Officer.
Regulatory Filings
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 26, 2026. This press release does not constitute an offer to sell or solicitation of an offer to buy in any jurisdiction where such action would be unlawful prior to registration or qualification.
Given the full exercise of the over-allotment option, what does this level of investor demand suggest about the current market appetite for life sciences-focused SPACs in late 2026?
How might Rainier Acquisition's broader global search strategy across multiple life science subsectors impact its timeline for identifying and closing a target business compared to more niche-focused peers?
With $86.25 million secured in the trust account, what are the specific financial thresholds or valuation ranges Rainier Acquisition is likely targeting for its initial business combination?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
